A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 378 participants.
Also called NCT03422653
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 378 participants
- Sponsor
- Registry
-
NCT03422653
-
- Other papers using this trial's data
- A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03422653. Randomized; double masking; primary purpose treatment. Start 2018-02-20 (actual); primary completion 2019-04-06 (actual). Results posted on 2022-04-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
- Condition
- Uremic Pruritus
- Intervention (Drug)
- CR845 0.5 mcg/kg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Cara Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct03422653- Content hash
39fcb2da7d71bd5a5bc0a4279d8084efb6800eec8d5180faa7b113138d0dfa03